Strategic Partners (STRAP) H2 2024 earnings summary

Executive summary

• Finalized US court case and settled with Zevra, resulting in a one-time positive impact of EUR 0.5 million in 2024.

• Broadened company strategy to include investments and partnerships beyond biotech, approved by Nasdaq and shareholders.

• Acquired investment property in Copenhagen valued at DKK 3.55 million and sold stake in CombiGene AB at near acquisition cost.

• Increased share capital by 18.12% through a DKK 5.3 million capital raise to support future investments.

• Initiated liquidation of US and Swiss subsidiaries, expecting completion in 2025.

Financial highlights

• Operating loss for 2024 was DKK 0.2 million, a significant improvement from DKK 27.0 million in 2023.

• Net result for 2024 was a loss of DKK 0.3 million, compared to a loss of DKK 26.0 million in 2023.

• General and administrative expenses reduced to DKK 2.9 million from DKK 27.0 million year-over-year.

• Cash, securities, and investments totaled DKK 23.5 million at year-end 2024, up from DKK 18.2 million in 2023.

• Net cash outflow from operating activities was DKK 3.4 million, down from DKK 20.0 million in 2023.

Outlook and guidance

• Anticipates a loss before tax of DKK 0–2 million for full-year 2025.

• Outlook subject to risks from limited business activities and future investment prospects.